20 August 2018 - South Korea’s Daewoong Pharmaceutical said Monday that Health Canada had granted marketing approval for its type A botulinum toxin drug Nabota, clearing the way for the product’s launch in North America.

Nabota has been approved by the Canadian drug regulator for the treatment of wrinkles in the forehead, according to the drugmaker. It is the first of Daewoong’s self-developed drugs to be approved for sales in a major global pharmaceutical market.

The regulatory clearance comes three months after Health Canada granted Good Manufacturing Practice certification to Daewoong’s Nabota production plant here in May.

Read Korean Herald article